In conclusion, estrogen-containing compounds capable of increasing ACE2/Ang-(1-7)/MasR may be a therapeutic option for the management of critically COVID-19 patients, but observational studies and randomized controlled trials are needed. The gene discussed is MAS1L; the disease is COVID-19.